Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 83,257 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: therapy Clear all
Completed Phase 4 Interventional Results available

Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD)

NCT00464698
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
Duloxetine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 4, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

COMT Inhibition Among Individuals With Comorbid AUD/ADHD

NCT03904498
View directory record Official record
Conditions
Alcohol Use Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 4, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

NCT01164163
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ruxolitinib phosphate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
24
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Sep 4, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of Varenicline for the Treatment of Cocaine Dependence

NCT01680887
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 4, 2026, 5:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

UTSW Depression Cohort: A Longitudinal Study of Depression

NCT02697487
View directory record Official record
Conditions
Depression, Other Diagnoses, Comorbidities, and Complications
Interventions
No treatment
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
10 Years to 89 Years
Enrollment
447 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 4, 2026, 5:34 AM EDT
Completed Not applicable Interventional Results available

A Collaborative Care Program to Improve Depression Treatment in Cardiac Patients

NCT00847132
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Arrhythmia, Depression
Interventions
Collaborative Care Treatment, Usual Care Treatment
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Sep 4, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder

NCT00411398
View directory record Official record
Conditions
General Anxiety Disorder, Social Anxiety Disorder
Interventions
Namenda/Memantine
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Sep 4, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma

NCT00000763
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
TNP-470
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 4, 2026, 5:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Functional Outcomes of Stay Strong Stay Healthy Program

NCT02677363
View directory record Official record
Conditions
Quality of Life, Aging, Memory Loss, Cardiovascular Diseases
Interventions
Resistance Exercise
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Sep 4, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer

NCT00068432
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Celecoxib, Gemcitabine Hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
11
States / cities
Fort Smith, Arkansas • Orlando, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 4, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Abbreviated Protocol for Two-Stage Exchange

NCT04662632
View directory record Official record
Conditions
Prosthetic Joint Infection
Interventions
VT-X7 Treatment System with Tobramycin Sulfate, Standard of Care, Two-stage exchange arthroplasty, VT-X7 Treatment System with Vancomycin Hydrochloride
Combination Product · Drug · Procedure
Lead sponsor
Osteal Therapeutics, Inc.
Industry
Eligibility
22 Years to 84 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Phoenix, Arizona • Torrance, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 4, 2026, 5:34 AM EDT
Terminated Not applicable Interventional Results available

The Pristine Post-Market Study

NCT05228132
View directory record Official record
Conditions
Kidney Failure, Chronic, Hemodialysis Complication, Hemodialysis Catheter Infection, Hemodialysis Access Failure, Central Venous Catheter Related Bloodstream Infection, End Stage Renal Disease
Interventions
Pristine™ Long-Term Hemodialysis Catheter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
6
States / cities
Dothan, Alabama • New Haven, Connecticut • Shreveport, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Sep 4, 2026, 5:34 AM EDT
Completed No phase listed Observational

Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests

NCT02252198
View directory record Official record
Conditions
Tuberculosis
Interventions
Epistem Genedrive® and MolBio Truenat™
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 4, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

NCT02675998
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
32
States / cities
Huntsville, Alabama • Riverside, California • Denver, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 4, 2026, 5:34 AM EDT
Completed No phase listed Observational

Effect of Post Discharge Follow-up on Readmission Rates for Congestive Heart Failure Patients

NCT01529463
View directory record Official record
Conditions
Congestive Heart Failure, Systolic Dysfunction
Interventions
Not listed
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Sep 4, 2026, 5:34 AM EDT
Active, not recruiting Phase 3 Interventional

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663
View directory record Official record
Conditions
Locally Advanced (Inoperable) or Metastatic Breast Cancer
Interventions
Capivasertib, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
893 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
40
States / cities
Tucson, Arizona • Fountain Valley, California • Glendale, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 4, 2026, 5:34 AM EDT
Active, not recruiting Not applicable Interventional

Pain Self-Management and Treatment Engagement for Patients Taking Opioids

NCT06855732
View directory record Official record
Conditions
Chronic Pain, Opioid Use Disorder, Opioid Misuse and Addiction
Interventions
Usual Care, Pain Self-Management
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
17
States / cities
Baltimore, Maryland • Allison Park, Pennsylvania • Blawnox, Pennsylvania + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 4, 2026, 5:34 AM EDT
Completed Phase 4 Interventional

Opiate-Induced Tolerance & Hyperalgesia in Pain Patients

NCT00246532
View directory record Official record
Conditions
Chronic Low Back Pain, Opioid-induced Hyperalgesia
Interventions
Morphine, Placebo
Drug
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 4, 2026, 5:34 AM EDT
Completed Phase 4 Interventional

Effects of Diazepam on RNS Detections

NCT05273398
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
nasal diazepam
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Sep 4, 2026, 5:34 AM EDT
Completed No phase listed Observational

Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis

NCT00586963
View directory record Official record
Conditions
Erosive Esophagitis, Reflux Esophagitis, GERD
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 22, 2010 · Synced Sep 4, 2026, 5:34 AM EDT
Not listed Phase 1Phase 2 Interventional

Metformin in Patients With Fragile X

NCT04141163
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Metformin, Placebo oral tablet
Drug
Lead sponsor
Rowan University
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stratford, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Sep 4, 2026, 5:34 AM EDT
Completed No phase listed Observational Results available

Hybrid Revascularization Observational Study

NCT01121263
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Sep 4, 2026, 5:34 AM EDT
Not yet recruiting Phase 2 Interventional

Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

NCT07588698
View directory record Official record
Conditions
Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin, Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone, Positron Emission Tomography (PET), Blood specimen collection, Questionnaires, Computerized tomography (CT)
Drug · Procedure · Behavioral
Lead sponsor
Carrie Ho, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 4, 2026, 5:34 AM EDT
Completed No phase listed Observational

Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure

NCT03387163
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
Sacubitril/Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 4, 2026, 5:34 AM EDT